Alterity Therapeutics Limited (ATHE)
Market: NASD |
Currency: USD
Address: 350 Collins Street
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Show more
📈 Alterity Therapeutics Limited Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$12.00
-
Upside/Downside from Analyst Target:
177.14%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.100000 |
- |
2023-01-09 |
- |
Stock split |
|
Total Amount for 2023: $0.100000 |
| 2016 |
- |
$0.166667 |
- |
2016-03-24 |
- |
Stock split |
|
Total Amount for 2016: $0.166667 |
📅 Earnings & EPS History for Alterity Therapeutics Limited
| Date | Reported EPS |
|---|
| 2025-02-28 | - |
📰 Related News & Research
No related articles found for "alterity therapeutics".
